Product Description
Gebro Pharma is developing Dexibuprofen as a treatment for pain. (Sourced from: https://www.gebro.com/en/produkte/eu-med-200-mg-pain-tablets/)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Bangladesh | Brazil | Chile | Colombia | Czech | Dominican Republic | Ecuador | Egypt | Germany | Greece | Hungary | India | Italy | Korea | Pakistan | Peru | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Switzerland | Turkey | Ukraine | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Gebro Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Pain, Postoperative
Phase 1: Osteoarthritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20202286 | P2 |
Not yet recruiting |
Pain, Postoperative |
None |
|
| CTR20230769 | P1 |
Not yet recruiting |
Osteoarthritis |
None |